July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
Proactive Investors : “ReNeuron Group agrees £80mln cell therapy licensing deal for China”
Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors : CFO ‘very pleased’ to be awarded £1.8m grant
To view the full article click here…
Proactive Investors : CFO ‘pleased’ with reformulation of degenerative diseases treatment
To view the full article click here…
CFO comments on publication of positive pre-clinical data fron retinitis pigmentosa programme
First Retinal Patient Receives Stem-Cell Therapy in ReNeuron’s Clinical Trial
For the article published by the Foundation for Fighting Blindness Click here..
Interview with Dr. Michael Young, pre-clinical investigator with ReNeuron’s hRPC retinal technology
https://soundcloud.com/trouttalks/trouttalks-ep7-dr-michael-young-human-retinal-progenitor-cell-therapy
Interview with Dr. Eric Pierce, Principal Investigator on ReNeuron’s Phase I/II clinical trial for Retinitis Pigmentosa
https://soundcloud.com/trouttalks/trouttalks-ep8-dr-eric-pierce-treatment-of-retinitis-pigmentosa
